Our further research resulted in the development of novel tricyclic histone deacetylase (HDAC) inhibitors, which showed higher cytotoxicity and better selectivity towards leukemic and lymphoma cell lines when compared with the reference drug and HDAC inhibitor vorinostat [30]. The gene discussed is HDAC9; the disease is lymphoma.